{"id":"carfilzomib-proteasome-inhibitor-intravenous","safety":{"commonSideEffects":[{"rate":"40%","effect":"Anemia"},{"rate":"30%","effect":"Thrombocytopenia"},{"rate":"20%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Carfilzomib inhibits the 20S proteasome, a protein complex involved in protein degradation.","oneSentence":"Proteasome inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:49:33.472Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT01572480","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-05-29","conditions":"Multiple Myeloma","enrollment":55},{"nctId":"NCT02318784","phase":"PHASE2","title":"Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2015-07-15","conditions":"Neuroendocrine Cancer","enrollment":62},{"nctId":"NCT03416374","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-02-18","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":45},{"nctId":"NCT02474927","phase":"PHASE2","title":"Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation","status":"COMPLETED","sponsor":"John F. McDyer, MD","startDate":"2015-11-01","conditions":"Lung Transplant Rejection","enrollment":22},{"nctId":"NCT01989325","phase":"PHASE2","title":"A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-11","conditions":"Advanced Multiple Myeloma","enrollment":77},{"nctId":"NCT00150462","phase":"PHASE1","title":"Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-09","conditions":"Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease","enrollment":48},{"nctId":"NCT01658904","phase":"PHASE1, PHASE2","title":"Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-07","conditions":"Multiple Myeloma, Leukemia, Plasma Cell","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Carfilzomib, proteasome inhibitor; intravenous","genericName":"Carfilzomib, proteasome inhibitor; intravenous","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Proteasome inhibitor Used for Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}